What 4 Analyst Ratings Have To Say About Dyne Therapeutics
Dyne Therapeutics (NASDAQ:DYN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Chardan Capital Maintains Buy on Dyne Therapeutics, Raises Price Target to $20
Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $17 to $20.
Analyst Says This Small Cap Biotech Firm Has ‘Very Valuable Therapeutic,’ Upgrades Stock
Raymond James has upgraded Dyne Therapeutics Inc (NASDAQ:DYN) from Outperform to Strong Buy and raised the price target to $27 from $16.…
Raymond James Upgrades Dyne Therapeutics to Strong Buy, Raises Price Target to $27
Raymond James analyst Steven Seedhouse upgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Strong Buy and raises the price target from $16 to $27.
$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades.
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Gainers
Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.
Raymond James Maintains Outperform on Dyne Therapeutics, Raises Price Target to $16
Raymond James analyst Steven Seedhouse maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $15 to $16.
Dyne Therapeutics: Q3 Earnings Insights
Dyne Therapeutics (NASDAQ:DYN) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:28 AM.
Here's what investors need to know about the announcement.
Dyne Therapeutics Receives FDA Fast Track Designation For DYNE-251 For The Treatment Of Duchenne Muscular Dystrophy
Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the